Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, has appointed Stuart Grant as executive vice president (EVP) and chief financial officer (CFO). Grant comes to Patheon following an accomplished career with increasing levels of responsibility in finance for several successful, global public companies.
Grant is joining Patheon after serving as senior vice president (SVP) and CFO of BioCryst Pharmaceuticals, where he was a key player in the creation and execution of a company-wide strategy that stabilised, funded and enabled future operations of the company. His responsibilities included the finance, information technology, supply chain operations, manufacturing and communications functions.
Prior to joining BioCryst, Grant was group CFO for Serono where he worked for 12 years, three years in his last position, until the company was acquired. Grant also spent 15 years in finance at Digital Equipment Company and several years working as a tax consultant and senior auditor for Price Waterhouse in Glasgow, Scotland.
Grant holds a Bachelor of Accountancy from the University of Glasgow, Glasgow, Scotland and is a chartered accountant with the Institute of Chartered Accountants of Scotland (ICAS).
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.